Serum Levels of Aryl Hydrocarbon Receptor Plasma Agonist Activity Are Reduced in Patients With NMOSD and Correlate With Disease Activity

By afschroeder • August 6, 2025

Tsaktanis T, Ammon L, Lößlein L, Peter A, Vandrey O, Naumann UJ, Behne M, Cook LJ, Levy M, Yeaman MR, Bennett JL, Rothhammer V; Guthy-Jackson Charitable Foundation CIRCLES Study Group. Serum Levels of Aryl Hydrocarbon Receptor Plasma Agonist Activity Are Reduced in Patients With NMOSD and Correlate With Disease Activity. Neurol Neuroimmunol Neuroinflamm. 2025 Sep;12(5):e200457. doi: 10.1212/NXI.0000000000200457. Epub 2025 Aug 5. PMID: 40763318.

Tags: Harbor UCLA, Infectious Diseases, Publications

Impact of metastatic pattern and histologic subtype on PD-(L)1 inhibitor efficacy in HER2-negative advanced gastric and gastroesophageal cancer: a meta-analysis

Tai D, Kim KI, Shah P, Park D, Kim L, Li J, Jung C, Guzman S, Brar G, Wu S, Castillo D. Impact of metastatic[...]

Investigating the Kidney-Gut-Brain Axis in CKD: Uremic Toxins and Brain Microhemorrhages

Zhao Y, Lee SM, Li W, Floriolli D, Chang P, Narasaki Y, You AS, Kalantar-Zadeh K, Rhee CM, Liu H, Tran T, Paganini-Hill A, Fisher[...]

Comparative Effectiveness of Lipid-Lowering Therapies in Increasing High-Density Lipoprotein Cholesterol Levels in Patients with Chronic Kidney Disease

Naim MAAZ, Thomas F, Streja E, Davis RL, Kalantar-Zadeh K, Sumida K, Kovesdy CP. Comparative Effectiveness of Lipid-Lowering Therapies in Increasing High-Density Lipoprotein Cholesterol Levels[...]